The Estrogen Receptor (ER) drives 75% of breast cancers. On activation, the ER recruits specific co-factors to form a transcriptionally active complex. These co-factors can modulate tumour growth and understanding their roles can help to identify new therapeutic targets.
chromatin loops and recruits several co-activators along with the mediator 23 complex. It is through these interactions that the ER is able to facilitate the 24 activation of RNA Pol II at the promoters of target genes [17] . Without the 25 coordination of the ER and these co-factors it therefore is not possible for 26 the efficient transcription of target genes to occur. 27 Further characterisation of ER co-factors could therefore be essential to 28 identify targets for novel treatment strategies. Successful examples of co-29 factor based approaches include studies demonstrating that the GREB1-ER-30 EZH2 transcriptional axis is directly involved in tamoxifen resistance [35] 31 or identifying the pioneer-factor FOXA1 as a key opportunity for future 32 interventions [18, 2] . This study aims to lay the ground work for future co-33 factor based therapies by presenting proteomic and genomic evidence that Figure 1 : (A) qPLEX-RIME enables the quantitative comparision of multiple conditions to idenfity key interactions between transcription factors on the chromatin. We stimulated ER+ breast cancer cell lines with estradiol and undertook a comparative analysis against an unstimulated control to identified the changes in the ER interacome on activation. (B) ER interacting proteins identified by qPLEX-RIME in MCF7. Figure 2 : (A) Lucierase Assay monitoring ER activity. ER activity in MCF7, T47D and MDA-MB-231 cell lines was monitored by Cignal ERE Reporter Assay. Both MCF7 and T47D cells showed a significant reduction in ER activity in response to ZMIZ1 knockdown. As expected, MDA-MB-231 cells showed no activity in all conditions but the positive, constitutively active, control.(B) Knockdown of ZMIZ1 in three cell lines, T47D, MCF7 and MDA-MB-231 all showed reduced proliferation. The effect was largest in the ER-postive cell lines, T47D and MCF7. We inferred the increased response to ZMIZ1 knockdown to imply that as ER singalling is the main driver in these two cell lines that ZMIZ1 expression levers had the greatest effect. In contrast the response in MDA-MB-231, a triple-negative breast cancer model, implies that ZMIZ1 has additional functionality independent of the estrogen receptor transcriptional complex, but this has a lesser effect on cell growth than its role in ER positive breast cancer.
WILLIAMS_ESR1_TARGETS_UP showed a significant reduction in ER transcriptional response (p = 0.047). Overall overlap of all 3 gene sets is low with 108 3 genes in common. All three gene sets gave a significant results (p = 2.3 ×10 −6 ,0.0001 & 3.5 115 ×10 −7 respectively).
116
On the basis of these results, we hypothesised that ZMIZ1 regulated a 117 subset of ER-regulated genes focused on cell cycle. The varied results for 118 GSEA of ER specific sets could then be explained as a result in variation in 119 genes represented in each of MSigDB gene sets and a lack of specificity to ER-120 ZMIZ1 signalling axis. To test our hypothesis were undertook GSEA against 121 the intersection of the REACTOME CELL CYCLE and the previously tested ER 122 specific gene sets (p = 0.0006). Repeating the analysis in T47D cell gave p 123 = 0.005 ( Figure S1 ). Figure 3A ).
173
These results were consistent with the ZMIZ1 functioning as a co-factor 174 of the ER in ER-positive breast cancer and that ZMIZ1 played a role in activity on ZMIZ1 knockdown. We therefore present evidence that ZMIZ1 191 has a role in modulating ER activated transcription that has not previously 192 been seen in other models. Further, we were able to show that within patient 193 samples the ZMIZ1 and ER expression correlated, and that the proteins are co-localised with in the nuclei of tumour cells.
In this study, we demonstrate that ZMIZ1 is able to interact with the 
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We would like to acknowledge the contribution from the CRUK Genomics, Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens. Signature values Figure S1 : GSEA analysis of RNA-seq +/-siZMIZ1. Row 1-2, GSEA of differentially expressed genes +/-siZMIZ1 at 6 hours after addition of E2. Row 3, (Left) Number of differentially expressed genes +/-siZMIZ1 at 3, 6, 12 and 24 hours after addition of E2.
(Middle and Right) GSEA of cell cycle specific ER responsive genes shows knockdown of ZMIZ1 targets these genes.
